Journal profile · CLINICAL NEUROLOGY
Multiple Sclerosis and Related Disorders
ISSN 2211-0348 · eISSN 2211-0356 · Elsevier · ENGLAND
Multiple Sclerosis and Related Disorders: CAS Zone 3 · Medicine (2025 upgraded edition); impact factor 2.89; hybrid open access; APC about USD 3,500; median 92 days to acceptance (115 articles, last 24 months); 569 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Multiple Sclerosis and Related Disorders is published by Elsevier and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Multiple Sclerosis Research Studies, Peripheral Neuropathies and Disorders and Systemic Sclerosis and Related Diseases, together about 61.1% of its articles. Its main subfields are Neurology. (generated from OpenAlex topic counts and CAS ranking data)
Multiple Sclerosis and Related Disorders is a comprehensive journal dedicated to advancing the understanding, diagnosis and treatment of multiple sclerosis (MS) and related immune-mediated and infectious diseases of the central nervous system (CNS). In recognition of the rapidly evolving landscape of research and clinical practice in this field, we aim to publish high-quality, innovative original research, thorough reviews, and expert opinions that push the boundaries of current knowledge. Our scope includes clinical neurology, neuroepidemiology, neurobiology, neuroimaging, neuroimmunology, genetics, biomarkers, neuropsychology, neurorehabilitation, and novel therapeutics. Multiple Sclerosis and Related Disorders is committed to promoting multidisciplinary dialogue and supporting the translation of research findings into improved patient care and outcomes. We welcome submissions of the following types of articles: Original Research; Reviews; Editorials; and Commentaries.
From the journal's Aims & Scope
Research area (LetPub): CLINICAL NEUROLOGY
Editor-in-chief Jeannette Lechner-ScottPublisher website
Editorial board by country: 1 in mainland China (about 2%); most named United States 21, United Kingdom 11, Australia 7, Switzerland 4, Canada 3 (65 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Multiple Sclerosis Research StudiesMedicine44.9%
- Peripheral Neuropathies and DisordersMedicine11.8%
- Systemic Sclerosis and Related DiseasesMedicine4.4%
- Polyomavirus and related diseasesMedicine4.3%
- Amyotrophic Lateral Sclerosis ResearchMedicine3.9%
- Long-Term Effects of COVID-19Medicine3.5%
- Systemic Lupus Erythematosus ResearchMedicine2.9%
- Balance, Gait, and Falls PreventionHealth Professions2.8%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Clinical Neurology | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Clinical Neurology | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Clinical Neurology | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 2.89LetPub ·
- Impact factor (publisher)
- 3Publisher website ·
- CiteScore 2026-06
- 5.4LetPub ·
- CiteScore (publisher)
- 5.4Publisher website ·
- SJR 2026-06
- 0.96LetPub ·
- SNIP 2026-06
- 0.97LetPub ·
- h-index
- 25LetPub ·
- h-index
- 88OpenAlex ·
- i10-index
- 2,486OpenAlex ·
- 2-year mean citedness
- 2.22OpenAlex ·
- Self-citation rate
- 16.7%LetPub ·
- Share of gold OA articles
- 22.66%LetPub ·
Volume
- Articles per year
- 495LetPub ·
Articles by year OpenAlex count · 6,745 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 674 | 207 | 127 |
| 2025 | 569 | 200 | 1,170 |
| 2024 | 699 | 220 | 3,016 |
| 2023 | 853 | 215 | 4,925 |
| 2022 | 744 | 311 | 8,359 |
| 2021 | 652 | 246 | 10,266 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
92 daysMedian, submission to acceptance · P25–P75 65 days – 128 days
- Acceptance to online
- median 1 days (115 articles)
- Submission to online
- median 94 days
- Sample
- 115 articles with submission and acceptance dates (1,205 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Submission to first decision
- 4 daysPublisher website ·
- First decision after review
- 54 daysPublisher website ·
- Submission to acceptance
- 115 daysPublisher website ·
- Acceptance to publication
- 2 daysPublisher website ·
- Peer review
- Single anonymous peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 3,500 / EUR 3,270 / GBP 2,800 / JPY 434,110 | — | — | |
| Publisher website | USD 3,690 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare6 items from the author guidelines
- Abstract
- ≤ 250 words
- Keywords
- 1–7
- Manuscript length
- ≤ 3,500 words
- Reference style
- Author–date
- Highlights
- Required
- Graphical abstract
- Optional
Article types accepted5, with length limits
- commentariesWe welcome submissions of the following types of articles: Original Research; Reviews; Editorials; and Commentaries.Length not stated
- editorialsWe welcome submissions of the following types of articles: Original Research; Reviews; Editorials; and Commentaries.Length not stated
- original researchFull length research papers will not normally be more than 3,500 words in length from the Introduction through the Discussion section and will preferably be sho…Length not stated
- research paperFull length research papers will not normally be more than 3,500 words in length from the Introduction through the Discussion section and will preferably be sho…main text ≤ 3,500 words
- reviewsWe welcome submissions of the following types of articles: Original Research; Reviews; Editorials; and Commentaries.Length not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, License & copyright, Open access, Peer review, Preprints
- AI use Declaration of generative AI use
Authors must declare the use of generative AI tools in the manuscript preparation process upon submission of the paper.Generative AI and AI-assisted technologies (“AI tools”) have been rapidly adopted in research and scholarly publishing, offering significant benefits while requiring clear standards for responsible and transparent use.Authors preparing a manuscript for this journal may use AI tool…
Source ↗Publisher website ·- Authorship Group authorship
Group authorship refers to the attribution of an article to a defined and named group of authors whose members have contributed to the work. Examples include research consortia, clinical trial groups, collaborative networks, task forces or working groups, expert panels or consensus groups, and participatory research groups. Group authorship must be declared on the title page at submission. When av…
Source ↗Publisher website ·- Conflicts of interest Declaration of competing interests
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence or bias their work. Examples of potential competing interests include:EmploymentConsultanciesStock ownershipHonorariaPaid expert testimonyPatent applications or registrationsGrants or any other fundingAffiliation with the journal as an Editor or Advisory Board …
Source ↗Publisher website ·- License & copyright License options
Authors will be offered open access user license options which will determine how you, and third parties, can reuse your open access article. We advise that you review these options and any funding body license requirements before selecting a license option.
Source ↗Publisher website ·- Open access Open access
We refer you to our open access information page to learn about open access options for this journal.
Source ↗Publisher website ·- Peer review Peer review
Single anonymized review process Model summary
This journal follows a single anonymized review process. Your submission will initially be assessed by our editors. If your submission is deemed suitable, it will typically be sent to be reviewed by a minimum of two reviewers for an independent expert assessment of the scientific quality. The decision as to whether your article is accepted or rejected for publication will be made by our editors.Re…
Source ↗Publisher website ·- Preprints Preprints
Preprint sharing allowed Model summary
Preprint sharingAuthors may share preprints in line with Elsevier's article sharing policy. Sharing preprints, such as on a preprint server, will not count as prior publication.We advise you to read our policy on multiple, redundant or concurrent publication.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Elsevier
- Country or region
- ENGLAND
- Language
- English
- ISSN
- 2211-0348
- Electronic ISSN
- 2211-0356
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗Publisher website
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Multiple Sclerosis and Related Disorders
What CAS zone is Multiple Sclerosis and Related Disorders in?
In the 2025 upgraded edition of the CAS Journal Ranking, Multiple Sclerosis and Related Disorders is in Zone 3 of Medicine, and in Zone 4 of the minor category Clinical Neurology. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Multiple Sclerosis and Related Disorders?
The latest impact factor listed by LetPub is 2.89; CiteScore 5.4, h-index 88.
How long does peer review take at Multiple Sclerosis and Related Disorders?
Based on the dates recorded on 115 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 92 days (interquartile range 65–128 days). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Multiple Sclerosis and Related Disorders?
According to the journal's author guidelines: Abstract: ≤ 250 words; Keywords: 1–7; Manuscript length: ≤ 3,500 words; Reference style: Author–date; Highlights: Required; Graphical abstract: Optional. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Multiple Sclerosis and Related Disorders based?
Of the 65 board members whose country the journal's board page names, 1 (about 2%) are in mainland China; the countries named most often are United States (21), United Kingdom (11) and Australia (7). Counted from the institutions listed on the board page; for reference only.
Which databases index Multiple Sclerosis and Related Disorders?
According to LetPub and DOAJ records, Multiple Sclerosis and Related Disorders is indexed in SCIE and Scopus.
Is Multiple Sclerosis and Related Disorders open access, and what is the APC?
Multiple Sclerosis and Related Disorders is a hybrid journal. For open-access publication: APC about USD 3,500.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .